Key Takeaways
- FlowTriever patients had three times fewer clinical deteriorations than those treated with CDT.
- Faster symptom improvement and hemodynamic recovery observed within 24 hours with FlowTriever.
- Significantly less ICU admission and reduced length of stay in hospitals for patients treated with FlowTriever.
- Zero patient deaths related to FlowTriever treatment at 7-day discharge and an impressively low all-cause mortality rate at 30-day follow-up.
A groundbreaking study has highlighted the remarkable efficacy of Inari Medical’s FlowTriever system in treating pulmonary embolism (PE), a critical condition that affects numerous patients worldwide. The PEERLESS Randomized Controlled Trial (RCT) has delivered compelling evidence favoring FlowTriever over traditional catheter-directed thrombolytics (CDT), marking a significant advancement in medical treatment. Conducted across 57 centers globally, this trial has set a new benchmark for PE intervention, emphasizing faster recovery and fewer complications.
The PEERLESS trial exhibited a decisive win with its primary composite endpoint, achieving a win ratio of 5.01 (p<0.001). Patients treated with FlowTriever experienced notably fewer clinical deteriorations and bailouts compared to those receiving CDT. This outcome has been driven by the superior efficacy of FlowTriever in rapidly resolving thrombus, thereby reducing the necessity for reintervention and ICU admissions. The study demonstrated improved hemodynamics and a quicker recovery of clinical symptoms, highlighting FlowTriever’s superiority over CDT.
Comprehensive Study Highlights
Led by a distinguished team of investigators, including Dr. Wissam Jaber and Dr. Carin Gonsalves, the study enrolled 550 intermediate-risk PE patients. It rigorously compared the outcomes of FlowTriever thrombectomy against CDT, excluding patients with absolute contraindications to thrombolytics. The findings underscored FlowTriever’s ability to deliver superior clinical outcomes while maintaining an excellent safety profile. Patients treated with FlowTriever experienced shorter hospital stays and fewer 30-day readmissions, reinforcing its effectiveness in enhancing patient recovery.
PEERLESS has not only highlighted the effectiveness of FlowTriever but also set a new standard for pulmonary embolism treatment. The trial’s success indicates a shift towards more efficient and less invasive procedures, reflecting the future direction of cardiovascular therapeutics. This study serves as a testament to Inari Medical’s commitment to advancing patient care through innovative solutions. These findings may influence clinical practice guidelines and encourage further research in this domain, ushering in a promising era of PE treatment advancements.
The PEERLESS trial
The PEERLESS trial has established FlowTriever as a leading tool in the treatment of intermediate-risk PE, demonstrating its potential to improve patient outcomes significantly. By reducing hospital resource utilization and enhancing safety profiles, FlowTriever offers a compelling alternative to traditional thrombolytic therapies.
As Inari Medical continues to pioneer research in this field, the medical community can anticipate further improvements in PE management. These developments may ultimately lead to broader adoption of mechanical thrombectomy, transforming the landscape of cardiovascular treatment and offering hope to countless patients globally.
Source: Â Inari Medical
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
